521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2016-12, Vol.27 (suppl_9)
Hauptverfasser:	Mok, T.S.K., Horn, L., Reck, M., Johnson, M.L., Tang, X., Lam, S., Shames, D.S., Waterkamp, D., Lopez-Chavez, A., Sandler, A., Giaccone, G., Liu, S.V.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	suppl_9
container_start_page
container_title	Annals of oncology
container_volume	27
creator	Mok, T.S.K. Horn, L. Reck, M. Johnson, M.L. Tang, X. Lam, S. Shames, D.S. Waterkamp, D. Lopez-Chavez, A. Sandler, A. Giaccone, G. Liu, S.V.
description
doi_str_mv	10.1093/annonc/mdw598.002
format	Article
fullrecord	<record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw598_002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdw598_002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c852-b61ccac638bb27b4e37874c8dc512cf3f0e2720b488796ce0e62722088ffba2b3</originalsourceid><addsrcrecordid>eNotkMtKw0AYhQdRsFYfwN2_TBdp55LLxF0JXgIRhXYfZiZ_bKRNQmZqbd_ItzS9rM754HAWHyGPjE4ZTcRMNU3bmNmm3IWJnFLKr8iIhVHiSxqwazKiCRd-HIrgltxZ-00pjRKejMhfyNmy_oTsvWt32DMhnmAO3UpZhGyWZRlYty330FagHB7adX3YbpQG70QT2NVuBUb1uu3WytUNeCeYgGpKQNd2ra1LBGWB5eBW2KtuD8OsG8bYOAte5-zlBn8dNrb-Qd869YWwSPMUvOeFfyyTe3JTqbXFh0uOyfLleZm--fnHa5bOc9_IkPs6YsYoEwmpNY91gCKWcWBkaULGTSUqijzmVAdSxklkkGI0MKdSVpVWXIsxYedb07fW9lgVXV9vVL8vGC2Oqouz6uKsuhhUi39tUHPb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Mok, T.S.K. ; Horn, L. ; Reck, M. ; Johnson, M.L. ; Tang, X. ; Lam, S. ; Shames, D.S. ; Waterkamp, D. ; Lopez-Chavez, A. ; Sandler, A. ; Giaccone, G. ; Liu, S.V.</creator><creatorcontrib>Mok, T.S.K. ; Horn, L. ; Reck, M. ; Johnson, M.L. ; Tang, X. ; Lam, S. ; Shames, D.S. ; Waterkamp, D. ; Lopez-Chavez, A. ; Sandler, A. ; Giaccone, G. ; Liu, S.V.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw598.002</identifier><language>eng</language><ispartof>Annals of oncology, 2016-12, Vol.27 (suppl_9)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mok, T.S.K.</creatorcontrib><creatorcontrib>Horn, L.</creatorcontrib><creatorcontrib>Reck, M.</creatorcontrib><creatorcontrib>Johnson, M.L.</creatorcontrib><creatorcontrib>Tang, X.</creatorcontrib><creatorcontrib>Lam, S.</creatorcontrib><creatorcontrib>Shames, D.S.</creatorcontrib><creatorcontrib>Waterkamp, D.</creatorcontrib><creatorcontrib>Lopez-Chavez, A.</creatorcontrib><creatorcontrib>Sandler, A.</creatorcontrib><creatorcontrib>Giaccone, G.</creatorcontrib><creatorcontrib>Liu, S.V.</creatorcontrib><title>521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNotkMtKw0AYhQdRsFYfwN2_TBdp55LLxF0JXgIRhXYfZiZ_bKRNQmZqbd_ItzS9rM754HAWHyGPjE4ZTcRMNU3bmNmm3IWJnFLKr8iIhVHiSxqwazKiCRd-HIrgltxZ-00pjRKejMhfyNmy_oTsvWt32DMhnmAO3UpZhGyWZRlYty330FagHB7adX3YbpQG70QT2NVuBUb1uu3WytUNeCeYgGpKQNd2ra1LBGWB5eBW2KtuD8OsG8bYOAte5-zlBn8dNrb-Qd869YWwSPMUvOeFfyyTe3JTqbXFh0uOyfLleZm--fnHa5bOc9_IkPs6YsYoEwmpNY91gCKWcWBkaULGTSUqijzmVAdSxklkkGI0MKdSVpVWXIsxYedb07fW9lgVXV9vVL8vGC2Oqouz6uKsuhhUi39tUHPb</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Mok, T.S.K.</creator><creator>Horn, L.</creator><creator>Reck, M.</creator><creator>Johnson, M.L.</creator><creator>Tang, X.</creator><creator>Lam, S.</creator><creator>Shames, D.S.</creator><creator>Waterkamp, D.</creator><creator>Lopez-Chavez, A.</creator><creator>Sandler, A.</creator><creator>Giaccone, G.</creator><creator>Liu, S.V.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161201</creationdate><title>521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)</title><author>Mok, T.S.K. ; Horn, L. ; Reck, M. ; Johnson, M.L. ; Tang, X. ; Lam, S. ; Shames, D.S. ; Waterkamp, D. ; Lopez-Chavez, A. ; Sandler, A. ; Giaccone, G. ; Liu, S.V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c852-b61ccac638bb27b4e37874c8dc512cf3f0e2720b488796ce0e62722088ffba2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mok, T.S.K.</creatorcontrib><creatorcontrib>Horn, L.</creatorcontrib><creatorcontrib>Reck, M.</creatorcontrib><creatorcontrib>Johnson, M.L.</creatorcontrib><creatorcontrib>Tang, X.</creatorcontrib><creatorcontrib>Lam, S.</creatorcontrib><creatorcontrib>Shames, D.S.</creatorcontrib><creatorcontrib>Waterkamp, D.</creatorcontrib><creatorcontrib>Lopez-Chavez, A.</creatorcontrib><creatorcontrib>Sandler, A.</creatorcontrib><creatorcontrib>Giaccone, G.</creatorcontrib><creatorcontrib>Liu, S.V.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mok, T.S.K.</au><au>Horn, L.</au><au>Reck, M.</au><au>Johnson, M.L.</au><au>Tang, X.</au><au>Lam, S.</au><au>Shames, D.S.</au><au>Waterkamp, D.</au><au>Lopez-Chavez, A.</au><au>Sandler, A.</au><au>Giaccone, G.</au><au>Liu, S.V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)</atitle><jtitle>Annals of oncology</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>27</volume><issue>suppl_9</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><doi>10.1093/annonc/mdw598.002</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0923-7534
ispartof	Annals of oncology, 2016-12, Vol.27 (suppl_9)
issn	0923-7534 1569-8041
language	eng
recordid	cdi_crossref_primary_10_1093_annonc_mdw598_002
source	Alma/SFX Local Collection; EZB Electronic Journals Library
title	521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A25%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=521TiP%20IMpower133:%20A%20phase%20I/III%20study%20of%20atezolizumab%20(atezo)%20with%20carboplatin%20(carbo)%20and%20etoposide%20as%201L%20therapy%20in%20patients%20(pts)%20with%20extensive-stage%20SCLC%20(ES-SCLC)&rft.jtitle=Annals%20of%20oncology&rft.au=Mok,%20T.S.K.&rft.date=2016-12-01&rft.volume=27&rft.issue=suppl_9&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw598.002&rft_dat=%3Ccrossref%3E10_1093_annonc_mdw598_002%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true